P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

McCaw Zachary R.; Wei Lee-Jen

首页> 外文期刊>JAMA: the Journal of the American Medical Association >P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

【24h】

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

机译：P2Y12抑制剂单药治疗经皮冠状动脉介入后的双抗血小板治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《JAMA: the Journal of the American Medical Association》 |2019年第16期|共1页
作者
McCaw Zachary R.; Wei Lee-Jen;
展开▼
作者单位

Harvard TH Chan Sch Publ Hlth Dept Biostat 655 Huntington Ave Boston MA 02115 USA;

Harvard TH Chan Sch Publ Hlth Dept Biostat 655 Huntington Ave Boston MA 02115 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention-Reply [J] . Hahn Joo-Yong, Song Young Bin, Gwon Hyeon-Cheol JAMA: the Journal of the American Medical Association . 2019,第16期

机译：P2Y12抑制剂单药治疗经皮冠状动脉干预后的双抗血小板治疗 - 答复
2. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention [J] . McCaw Zachary R., Wei Lee-Jen JAMA: the Journal of the American Medical Association . 2019,第16期

机译：P2Y12抑制剂单药治疗经皮冠状动脉介入后的双抗血小板治疗
3. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized ClinicalTrial (vol 321, pg 2428, 2019) [J] . Hahn J. Y., Song Y. B., Oh J. H. JAMA: the Journal of the American Medical Association . 2019,第13期

机译：P2Y12抑制剂单药治疗对经皮冠状动脉干预患者心血管事件的影响：智能选择随机诊断（Vol 321，PG 2428,2019）
4. Evaluation of Matrix Metalloproteinase-9 (MMP-9) and its tissue inhibitor of metalloproteinase-1 (Timp-1) in patients with coronary syndromes after percutaneous intervention(PCI) [C] . Revnic F., Revnic C.R., Nica A., International Congress on Coronary Artery Disease . 2011

机译：经皮干预后冠状动脉综合征患者中基质金属蛋白酶-9（MMP-9）及其组织抑制剂及其组织抑制剂（PCI）
5. The lived experience of heart attack: Individual accounts of primary percutaneous coronary intervention survivors [D] . Laberge, Carol G. 2012

机译：心脏病发作的实际经验：主要经皮冠状动脉介入治疗幸存者的个人资料
6. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China [O] . Yi Zhang, Xiu-Jin Shi, Wen-Xing Peng, 2020

机译：经皮冠状动脉干预后实施CYP2C19基因型引导抗血小板治疗抗血小板治疗对急性冠状动脉综合征患者P2Y12抑制剂选择及临床结果的影响：中国的真实研究
7. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials [O] . Daniele Giacoppo, Yuji Matsuda, Luca Nai Fovino, 2020

机译：短双抗血小板疗法，其次是P2Y12抑制剂单疗法与第二代药洗脱支架经皮冠状动脉干预后的延长双抗血小板治疗：随机临床试验的系统评价和荟萃分析

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

著录项

相似文献

相关主题

期刊订阅